1. Home
  2. ALLO vs SRFM Comparison

ALLO vs SRFM Comparison

Compare ALLO & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • SRFM
  • Stock Information
  • Founded
  • ALLO 2017
  • SRFM 2011
  • Country
  • ALLO United States
  • SRFM United States
  • Employees
  • ALLO N/A
  • SRFM N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • SRFM Transportation Services
  • Sector
  • ALLO Health Care
  • SRFM Consumer Discretionary
  • Exchange
  • ALLO Nasdaq
  • SRFM Nasdaq
  • Market Cap
  • ALLO 231.9M
  • SRFM 185.9M
  • IPO Year
  • ALLO 2018
  • SRFM 2023
  • Fundamental
  • Price
  • ALLO $1.11
  • SRFM $4.06
  • Analyst Decision
  • ALLO Strong Buy
  • SRFM Buy
  • Analyst Count
  • ALLO 10
  • SRFM 4
  • Target Price
  • ALLO $8.88
  • SRFM $5.75
  • AVG Volume (30 Days)
  • ALLO 3.8M
  • SRFM 2.6M
  • Earning Date
  • ALLO 11-06-2025
  • SRFM 08-12-2025
  • Dividend Yield
  • ALLO N/A
  • SRFM N/A
  • EPS Growth
  • ALLO N/A
  • SRFM N/A
  • EPS
  • ALLO N/A
  • SRFM N/A
  • Revenue
  • ALLO N/A
  • SRFM $107,372,000.00
  • Revenue This Year
  • ALLO N/A
  • SRFM N/A
  • Revenue Next Year
  • ALLO $100.00
  • SRFM $18.06
  • P/E Ratio
  • ALLO N/A
  • SRFM N/A
  • Revenue Growth
  • ALLO N/A
  • SRFM N/A
  • 52 Week Low
  • ALLO $0.86
  • SRFM $1.02
  • 52 Week High
  • ALLO $3.78
  • SRFM $9.91
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 44.66
  • SRFM 44.02
  • Support Level
  • ALLO $1.06
  • SRFM $3.80
  • Resistance Level
  • ALLO $1.18
  • SRFM $4.14
  • Average True Range (ATR)
  • ALLO 0.08
  • SRFM 0.29
  • MACD
  • ALLO 0.01
  • SRFM -0.04
  • Stochastic Oscillator
  • ALLO 31.25
  • SRFM 18.80

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About SRFM Surf Air Mobility Inc.

Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.

Share on Social Networks: